Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02520011
Title Alvocidib Biomarker-driven Phase 2 AML Study
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Alvocidib

Cytarabine + Mitoxantrone

Age Groups: adult
Covered Countries USA | ESP | CAN


No variant requirements are available.